Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cosibelimab + Prednisone + Sirolimus |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cosibelimab | Unloxcyt | CK-301|CK 301|TG-1501|TG1501|TG 1501|cosibelimab-ipdl | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 | Unloxcyt (cosibelimab) is a human monoclonal antibody against PD-L1 (CD274), which may block immune checkpoint, and lead to anti-tumor immune response (PMID: 37848259). Unloxcyt (cosibelimab) is FDA approved for use in adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation (FDA.gov). |
| Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). | |
| Sirolimus | Rapamune | Rapamycin | mTORC1 Inhibitor 9 | Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection and for patients with lymphangioleiomyomatosis (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07426484 | FDA approved | Cosibelimab Cosibelimab + Everolimus + Prednisone Cosibelimab + Prednisone + Sirolimus | Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy | Not yet recruiting | USA | 0 |